Business
GeneDx Announces Partnership with Komodo Health to Expand Access to World’s Largest Rare Disease Dataset
The Company will also participate in a World Orphan Drug Congress panel presentation highlighting the role of genomic sequencing in advancing precision
About this update from Genedx Holdings Corp.
[{"type":"text","content":"The Company will also participate in a World Orphan Drug Congress panel presentation highlighting the role of genomic sequencing in advancing precision medicine\nSTAMFORD, Conn., April 23, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced a strategic partnership with Komodo Health, a premier healthcare technology company for the pharmaceutical industry. The new partnership will increase access to GeneDx's extensive de-identified rare disease data set, now available through Komodo Health’s MapEnhance offering, including data from more than 500,000 exomes, enabling biopharma companies to access genetic insights that can help inform drug pipelines and accelerate clinical trial enrollment. “The partnership between GeneDx and Komodo Health represents a milestone in advancing the understanding of rare disease and its associated drug development”, said Melanie Duquette, Chief Growth Officer, GeneDx. \"We continue to see increased investment in rare disease drug discovery and want to help accelerate access to these life changing treatments by making our data more easily accessible to the companies on the forefront of these discoveries.” GeneDx's rare disease data set is recognized for its depth and accuracy, making it a valuable resource for biopharmaceutical companies seeking to identify novel therapeutic targets and optimize clinical trial design. As a MapEnhance specialty partner, GeneDx’s rich repository of de-identified genetic data will be accessible through Komodo’s end-to-end platform, to help companies unlock deeper insights into genetically based disease and accelerate new breakthroughs and treatments for patients. \"Combining the power of GeneDx’s genetic intelligence with Komodo’s comprehensive and longitudinal view into patient journeys is going to be a massive accelerant for companies looking to advance precision medicine and help to pave the way for more personalized treatments for patients,” said Brad Kelley, General Manager of MapEnhance, Komodo Health. “We are thrilled to welcome GeneDx to the MapEnhance family and help our customers more quickly unravel the intricate genetic underpinnings of diseases.\" GeneDx is continuing to showcase its value to biopharma companies through its participation in the World Orphan Drug Congress meeti...